Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short vs Prolonged Antibiotic Infusion for Febrile Neutropenia
NCT02463747Phase 4Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jun 2015
- Primary completion
- Jun 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam, ceftazidime and meropenem in febrile neutropenia (FN) (2 arms), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: A successful response to treatment at 5 days. Status: unknown.
02
Drugs
piperacillin + tazobactamceftazidimemeropenem
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT02463747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02463747.